Cytotoxic compounds from invasive salvinias (Salvinia spp.) against human tumor cells

Tech ID:
2012.054.SFAU
Description:

Novel plant-derived compounds that have cytotoxic properties against cancer cells and therefore may be potent anticancer therapeutics. These compounds are derived from giant salvinia, one of the most noxious invasive species of plants in the world. The compounds showed selective cytotoxic activity against several human cancer cell lines, including forms of lung cancer, prostate cancer, pancreatic cancer, breast cancer, and leukemia.

 

Background:

Giant salvinia (Salvinia molesta) is one of the most widespread and environmentally, economically and socially destructive invasive plant species in the world. The salvinia also provides habitat for snails that are intermediate hosts for Schistosoma sp. which causes the parasitic disease Schistosomiasis, the second most socioeconomically devastating parasitic disease after malaria. However, the plant may prove beneficial for its novel compounds, and would provide an additional financial incentive to control this plant by harvesting it for pharmaceutical use.

 

 Benefits and Advantages:

·         Several plant-derived molecules have been effective and are highly valued by pharmaceutical companies, including Taxol and Abraxane

·         Plant-derived compounds represent a $4.4 Billion market (33% of the market share)

·         Plant-derived compounds and their analogs offer novel therapeutic alternatives

·         Source of compounds are from a globally-abundant species, and extraction of the compounds would be economically viable globally

 

IP Status: Patent pending

Patent Information:
Category(s):
Therapeutics
For information contact:
John Fritz
Sr. Business Development Manager
Office of Technology Commercialization
FRITZJA@UTHSCSA.EDU
Inventors:
Shiyou Li
Ping Wang
Guangrui Deng
Wei Yuan
Zushang Su
Keywords:
Drugs